Prazosin for Raynaud's phenomenon in progressive systemic sclerosis
Sübutlu məlumatların xülasələri
06.08.2013 • Sonuncu dəyişiklik 06.08.2013
Editors
Prazosin may be modestly effective in the treatment of Raynaud's phenomenon secondary to scleroderma.
Two trials with a total of 40 patients were included in a Cochrane review . Prazosin has been found in two randomised cross-over trials to be more effective than placebo. However, the positive response is modest and side effects are not rare.
Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison) and by potential reporting bias.
Ədəbiyyat
- Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 1998;(2):CD000956.